Evaluation of Plasma Circulating Cell Free DNA Concentration and Integrity in Patients with Prostate Cancer in Jamaica: A Preliminary Study.
cancer
cell free
circulating DNA
integrity
prostate
Journal
Diseases (Basel, Switzerland)
ISSN: 2079-9721
Titre abrégé: Diseases
Pays: Switzerland
ID NLM: 101636232
Informations de publication
Date de publication:
07 Sep 2020
07 Sep 2020
Historique:
received:
04
08
2020
revised:
04
09
2020
accepted:
05
09
2020
entrez:
10
9
2020
pubmed:
11
9
2020
medline:
11
9
2020
Statut:
epublish
Résumé
Cell free circulating DNA (cfcDNA) is a promising diagnostic tool for prostate cancer (PCa). This study aimed to measure the cfcDNA concentration and integrity in PCa patients using quantitative polymerase chain reaction (qPCR) analysis. This study also assessed the correlation between these molecular biomarkers with total prostate-specific antigen (PSA), Gleason score, prostate volume, and age. Eleven PCa patients and 9 persons with benign prostatic hyperplasia (BPH) were recruited. Blood samples were collected before prostate biopsy and plasma quantified by qPCR amplification of the ALU 115 DNA sequence, with the ratio of ALU 247 to ALU 115 reflecting cfcDNA integrity. There were no significant differences in median, interquartile range (IQR) cfcDNA concentration or cfcDNA integrity between the patients with PCa (47.9 (214.93) ng/mL; 0.61 (0.49)) and persons with BPH (41.5 (55.13) ng/mL, cfcDNA concentration was relatively nonsignificantly higher in PCa patients in comparison to persons with BPH, whereas cfcDNA integrity was similar in both groups. Though limited in sample size, this study shows that cfcDNA concentration may be a potentially valuable noninvasive biomarker for the diagnosis of PCa.
Sections du résumé
BACKGROUND
BACKGROUND
Cell free circulating DNA (cfcDNA) is a promising diagnostic tool for prostate cancer (PCa). This study aimed to measure the cfcDNA concentration and integrity in PCa patients using quantitative polymerase chain reaction (qPCR) analysis. This study also assessed the correlation between these molecular biomarkers with total prostate-specific antigen (PSA), Gleason score, prostate volume, and age.
METHODS
METHODS
Eleven PCa patients and 9 persons with benign prostatic hyperplasia (BPH) were recruited. Blood samples were collected before prostate biopsy and plasma quantified by qPCR amplification of the ALU 115 DNA sequence, with the ratio of ALU 247 to ALU 115 reflecting cfcDNA integrity.
RESULTS
RESULTS
There were no significant differences in median, interquartile range (IQR) cfcDNA concentration or cfcDNA integrity between the patients with PCa (47.9 (214.93) ng/mL; 0.61 (0.49)) and persons with BPH (41.5 (55.13) ng/mL,
CONCLUSION
CONCLUSIONS
cfcDNA concentration was relatively nonsignificantly higher in PCa patients in comparison to persons with BPH, whereas cfcDNA integrity was similar in both groups. Though limited in sample size, this study shows that cfcDNA concentration may be a potentially valuable noninvasive biomarker for the diagnosis of PCa.
Identifiants
pubmed: 32906694
pii: diseases8030034
doi: 10.3390/diseases8030034
pmc: PMC7564624
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer Genet. 2019 Jun;235-236:65-71
pubmed: 31105051
Int J Biol Markers. 2010 Apr-Jun;25(2):79-86
pubmed: 20544686
Oncol Res. 2004;14(9):439-45
pubmed: 15490975
Tumour Biol. 2013 Apr;34(2):983-6
pubmed: 23269609
Cancer Lett. 2004 Mar 18;205(2):173-80
pubmed: 15036649
Ann N Y Acad Sci. 2004 Jun;1022:76-80
pubmed: 15251943
DNA Cell Biol. 2008 Aug;27(8):415-21
pubmed: 18694299
Cancer Res. 1986 Mar;46(3):1535-8
pubmed: 2417706
Neoplasia. 2001 Jan-Feb;3(1):62-9
pubmed: 11326317
Anticancer Res. 2013 Oct;33(10):4521-9
pubmed: 24123025
Int Urol Nephrol. 2013 Aug;45(4):1023-8
pubmed: 23779229
Clin Chem Lab Med. 2008;46(3):311-7
pubmed: 18254709
Ann Med. 2001 Mar;33(2):130-41
pubmed: 11327116
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3260-5
pubmed: 10737792
Clin Chem. 2009 Mar;55(3):559-67
pubmed: 19131636
P T. 2015 Sep;40(9):572-4
pubmed: 26417175
J Egypt Natl Canc Inst. 2016 Dec;28(4):235-242
pubmed: 27634416
Nat Rev Cancer. 2011 Jun;11(6):426-37
pubmed: 21562580
J Clin Oncol. 2006 Sep 10;24(26):4270-6
pubmed: 16963729
Clin Biochem. 2002 Mar;35(2):143-5
pubmed: 11983350
Clin Chem. 2009 Mar;55(3):587-9
pubmed: 19246404
Int Braz J Urol. 2015 Sep-Oct;41(5):898-905
pubmed: 26689514
Am J Clin Pathol. 2008 May;129(5):756-62
pubmed: 18426736
Clin Cancer Res. 2009 Feb 1;15(3):1032-8
pubmed: 19188176
Transfusion. 2001 Feb;41(2):276-82
pubmed: 11239235
Mol Med Rep. 2010 Sep-Oct;3(5):883-7
pubmed: 21472330
Clin Cancer Res. 2006 Aug 1;12(15):4569-74
pubmed: 16899603
Clin Chim Acta. 2002 Jul;321(1-2):77-87
pubmed: 12031596
Eur Urol. 2014 Jan;65(1):124-37
pubmed: 24207135
J Clin Lab Anal. 2012 Nov;26(6):467-72
pubmed: 23143630
Ann N Y Acad Sci. 2008 Aug;1137:218-21
pubmed: 18837950
Tumour Biol. 2013 Oct;34(5):2921-7
pubmed: 23715778
Cancer Res. 2003 Jul 15;63(14):3966-8
pubmed: 12873992
Br J Cancer. 2011 Jul 12;105(2):239-45
pubmed: 21712823
Dis Markers. 2016;2016:4358292
pubmed: 27594734
Nat Rev Cancer. 2002 Dec;2(12):918-26
pubmed: 12459730
Clin Chem. 2007 Sep;53(9):1609-14
pubmed: 17712000
Mod Pathol. 2008 Sep;21(9):1156-67
pubmed: 18567993
Nature. 1998 Mar 19;392(6673):300-3
pubmed: 9521327
BJU Int. 2006 Sep;98(3):544-8
pubmed: 16925751
Int J Cancer. 2008 Jan 1;122(1):138-43
pubmed: 17764114
Clin Chem. 2006 Jun;52(6):1062-9
pubmed: 16723681
Cancer Manag Res. 2019 May 16;11:4549-4556
pubmed: 31191016
Pancreas. 1998 Jul;17(1):89-97
pubmed: 9667526
Nature. 2001 Feb 15;409(6822):860-921
pubmed: 11237011
Clin Cancer Res. 2012 Oct 15;18(20):5719-30
pubmed: 23014523
Genes Dev. 2000 Oct 1;14(19):2410-34
pubmed: 11018010
Ann Surg Oncol. 2011 Sep;18(9):2461-8
pubmed: 21416156
Cancer Epidemiol. 2013 Oct;37(5):619-24
pubmed: 23850146
Methods Mol Biol. 2013;1049:35-51
pubmed: 23913207
Clin Chim Acta. 2009 Jun 27;404(2):100-4
pubmed: 19281804
Nature. 1993 Jun 10;363(6429):558-61
pubmed: 8505985